Approvals· August 31, 2026 · 18 min read
Stelara's Pediatric UC License Does Not Write Wezlana Pediatric IBD Substitution
By Ran Chen#Biosimilars#Interchangeability#Purple Book
Topic
Purple Book
Biological product listings, biosimilar/interchangeable status, reference products, and exclusivity clues.
Pricing & Access· August 18, 2026 · 18 min read
Ziihera's August 25 Gastric Decision: Bispecific vs Trastuzumab Biosimilars
By Ran Chen#Oncology#HER2#Biosimilars
Biosimilars· August 17, 2026 · 18 min read
FDA Biosimilar Device Guidance: Presentations That Are Not Interchangeable
By Ran Chen#Biosimilars#Interchangeability#Purple Book
Biosimilars· August 7, 2026 · 14 min read
Osteoporosis access landscape: Prolia's 10 denosumab biosimilars and Evenity
By Ran Chen#Biosimilars#Purple Book#Payer Policy
Pricing & Access· July 16, 2026 · 23 min read
Atopic dermatitis systemic access: Dupixent, JAK inhibitors, and biologics
Pricing & Access· July 14, 2026 · 18 min read
Generalized Myasthenia Gravis (gMG) Access and Dosing Landscape
By Ran Chen#Rare Disease#Payer Policy#HCPCS Coding
Pricing & Access· July 14, 2026 · 20 min read
PNH Access Landscape: C5 Blockers, Orals, and the Biosimilar Cliff
By Ran Chen#Rare Disease#Payer Policy#HCPCS Coding
Pricing & Access· July 11, 2026 · 16 min read
Sanofi Portfolio Dossier: Dupixent Growth, Lantus Cliff, and Altuviiio Pivot
By Ran Chen#Immunology#Orange Book#Purple Book
Pricing & Access· July 10, 2026 · 21 min read
AstraZeneca Portfolio Dossier: Farxiga Cliff, Enhertu Pivot, and Soliris Conversion
By Ran Chen#Orange Book#Purple Book#Medicare Part D
Pricing & Access· July 9, 2026 · 18 min read
AbbVie Portfolio Dossier: Skyrizi, Rinvoq, and 2030s Patent Cliffs
By Ran Chen#Immunology#Orange Book#Purple Book